Bio-Rad Posts Big Q2 Revenue, Profit Gains on DiaMed Contribution | GenomeWeb
NEW YORK (GenomeWeb News) – Bio-Rad Laboratories reported after the close of the market on Tuesday that its second-quarter revenues rose 33.4 percent and its net income increased 68.9 percent due largely to the contribution of DiaMed Holding, a developer of blood-typing reagents and screening tools that Bio-Rad purchased last October for $400 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.